Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2023
Biotech
ASH: Editas shares data for mid-stage sickle cell disease asset
After two landmark FDA approvals in sickle cell disease, Editas is sharing data for its gene-edited candidate designed to tackle the same condition.
Gabrielle Masson
Dec 11, 2023 2:33pm
Electra picks commercially-minded Kathy Dong as next CEO
Dec 11, 2023 7:00am
ASH: AstraZeneca shows longer term benefits of next-gen PNH drug
Dec 11, 2023 5:58am
ASH: Regeneron’s near-approval bispecific shines again
Dec 11, 2023 5:25am
ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med
Dec 11, 2023 4:30am
Poseida makes case for safety of Roche-partnered nonviral CAR-T
Dec 10, 2023 12:00pm
